1. Pink Sheet
  2. >>Geography
  3. >>Europe

EU Regulators Gear Up for Alzheimer’s Treatment Challenges

 
• By Anabel Costa-Ferreira

Many of the recommendations listed in a new report, which aims to prepare the European medicines regulatory network (EMRN) for Alzheimer’s disease development challenges, will form part of EMRN’s future plans.

A Clear, Universal Definition Of Alzheimer's Disease Is Lacking (Shutterstock)
Key Takeaways
  • The EU Innovation Network has issued a horizon scanning report to help the EU medicines regulatory network (EMRN) understand and proactively address the challenges and opportunities in the Alzheimer's disease landscape.
  • It points to several challenges relating to AD, including the limited understanding of the disease pathophysiology and the lack of a universal definition for the disease.
  • The report includes recommendation to adapt the EMRN, minimize regulatory bottlenecks, support developers and facilitate innovation.
  • The European Medicines Agency says many of the recommendations listed in the report will be added to the upcoming three-year work plan of its Central Nervous System Working Party.

Efforts are underway to enhance the ability of EU medicines regulators to review new treatments for Alzheimer’s disease (AD) that may be heading their way in the near future.

Many of the recommendations listed in a new horizon scanning report, which aims to help the EU medicines regulatory network (EMRN) proactively address upcoming challenges...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

US ‘Most Favored Nation’ Pricing Could be Game Changer for Drug Access In Germany

 
• By Francesca Bruce

In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.

ClinicalTrials.gov Or ISRCTN: Getting Transparency Right For UK Trials

 
• By Vibha Sharma

ISRCTN’s systems are being redesigned to facilitate compliance with upcoming requirements in the UK’s clinical trials legislation.

Spain Slashes Wait Between EU Drug Authorization And Financing Decisions

 
• By Francesca Bruce

Spanish authorities say that that timelines for drug reimbursement decisions can be improved further with the right submissions from companies.

Spain Beats England To Tevimbra Reimbursement Recommendations

 
• By Francesca Bruce

Spanish authorities have published more pricing and reimbursement reports as part of a new drive to increase transparency.

More from Pathways & Standards

UroGen’s Mitomycin: Are Randomized Trials For Bladder Cancer Necessary?

 
• By Sue Sutter

The Oncologic Drugs Advisory Committee will vote on the risk-benefit of UGN-102 for low-grade, intermediate-risk, non-muscle invasive bladder cancer based on data from a single-arm trial, but the FDA also seeks input on requiring randomized studies for future treatments.

Life After Loper: Vaping Case Shows US FDA Retains Considerable Deference

 
• By Craig Bleifer, Royce DuBiner, Max Bogost, Michael Brody, and Allyson Maur

A US Supreme Court ruling in favor of the agency in an e-cigarette case has implications for drugs and other medical products as the justices decided not to disturb the FDA’s ‘change in position’ authority, while also creating a complex new landscape.

US FDA Legislative Lead Calls For User Fee Reforms As Renewal Talks Near

 
• By Sarah Karlin-Smith

Deputy FDA Commissioner Grace Graham acknowledged the importance of user fees, while also calling for restructuring. She also said part of MAHA's mission is to reexamine uses of drugs not supported by data.